Rinki Agarwal

Publications (2)5.33 Total impact

• Article: Inherited predisposition to gastrointestinal stromal tumor.

  Rinki Agarwal, Mark Robson
  [show abstract] [hide abstract]
  ABSTRACT: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract and are a relatively recently identified category of mesenchymal tumors. Germline mutations in a number of different genes predispose to GIST. This article discusses familial GIST syndrome, Carney triad, Carney-Stratakis syndrome, and neurofibromatosis type 1, and addresses the recognition of an inherited predisposition in GIST patients.
  Hematology/oncology clinics of North America 03/2009; 23(1):1-13, vii. · 2.05 Impact Factor
• Article: Macrophage migration inhibitory factor expression in ovarian cancer.

  Rinki Agarwal, Dong Hee Whang, Ayesha B Alvero, Irene Visintin, Yinglei Lai, Elliot A Segal, Peter Schwartz, David Ward, Thomas Rutherford, Gil Mor
  [show abstract] [hide abstract]
  ABSTRACT: We evaluated the hypothesis that ovarian cancer patients have significantly higher levels of serum macrophage migration inhibitory factor (MIF). MIF levels were determined by enzyme-linked immunosorbent assay (ELISA) in epithelial ovarian cancer cell lines and immortalized normal ovarian surface epithelial cells and in serum of ovarian cancer patients (n = 54) and age-matched healthy women (n = 60). To determine the impact of Toll-like receptor-4 ligation on MIF levels, cells were treated for 48 hours with lipopolysaccharide. Cancer cells, but not normal cells, secrete significant amounts of MIF. This correlates in vivo, where serum MIF levels are significantly higher in ovarian cancer patients. Treatment of cancer cells with lipopolysaccharide induced a significant increase in MIF secretion. MIF may be relevant in the process of ovarian cancer formation and progression. The events leading to the induction of MIF expression and its contribution to ovarian cancer progression may open new venues for targeted therapy.
  American journal of obstetrics and gynecology 04/2007; 196(4):348.e1-5. · 3.28 Impact Factor